More than 3.9 million patients are expected to be treated for degenerative disc disease in the U.S. by 2028, according to a report from Coherent Market Insights.
Five things to know:
1. The U.S. degenerative disc disease treatment market is expected to grow 5.9 percent from 2021 to 2028.
2. Key trends in the market include a pipeline of treatments expected to drive growth. The report cited Minneapolis-based University of Minnesota's clinical trial of a combination of drugs and Iowa City-based University of Iowa's clinical trial of Tranexamic Acid in lumbar interbody spinal fusion.
3. Late stage treatment is expected to hold a dominant position in the market.
4. Key players in the market are focusing on developing and launching novel therapeutic treatments.
5. Major companies mentioned in the report include AnGes, Bone Therapeutics, DiscGenics, Ankasa Regenerative Therapies, Smith+Nephew and Spine BioPharma.